

LAHIVE  
&  
COCKFIELD  
L L P

COUNSELLORS AT LAW  
28 STATE STREET  
BOSTON, MASSACHUSETTS 02109-1784  
TELEPHONE (617) 227-7400  
FAX (617) 742-4214  
www.lahive.com

JOHN A. LAHIVE, JR. (1928-1997)  
THOMAS V. SMURZYNSKI  
GIULIO A. DeCONTI, JR.  
ELIZABETH A. HANLEY  
AMY BAKER MANDRAGOURAS  
ANTHONY A. LAURENTANO  
KEVIN J. CANNING  
JANE E. REMILLARD  
DeANN FORAN SMITH  
DEBRA J. MILASINCIC, Ph.D.  
WILLIAM A. SCOFIELD, JR.  
SIBLEY P. REPERT  
DAVID R. BURNS  
JOHN S. CURRAN  
SEAN D. DETWEILER  
MEGAN E. WILLIAMS, Ph.D.  
LISA DIROCCO TYNER  
HATHAWAY P. RUSSELL \*  
MARIA LACCOTRIPE ZACHARAKIS, Ph.D.

MERIDETH C. ARNOLD  
DANIELLE L. HERRITT  
EUIHOON LEE \*\*  
MANEESH GULATI  
CYNTHIA M. SOROOS  
PETER W. DINI, Ph.D.  
MICHAEL J. BASTIAN, Ph.D.  
CHRISTOPHER J. McKENNA  
VINCENT P. LOCCISANO  
JAMES M. McKENZIE

SENIOR COUNSEL  
JAMES E. COCKFIELD

OF COUNSEL  
JEREMIAH LYNCH  
JEANNE M. DIGIORGIO  
CYNTHIA L. KANIK, Ph.D.  
JOHN D. LANZA

1642  
JFW/HF  
PATENT AGENTS  
JONATHAN M. SPARKS, Ph.D.  
ANDRINA WILLIAMS ZINK  
CRISTIN E. HOWLEY, Ph.D.  
JILL ANN MELLO, Ph.D.  
CHRISTOPHER E. DRABIK  
JAMES H. VELEMA

TECHNICAL SPECIALISTS  
CATHERINE M. BISHOP  
JACOB G. WEINTRAUB  
DEBORAH L. NAGLE, Ph.D.  
ANNE JACQUELINE WIZEMAN, Ph.D.  
BRIAN C. TRINQUE, Ph.D.  
CHRISTOPHER R. COWLES, Ph.D.  
W. ELANA WANG  
CYNTHIA M. GILBERT

\* Admitted in TX only  
\*\* Admitted in CT only

November 2, 2004

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Re: U.S. Patent Application No.: 09/626,219  
For: *TREATMENT OF FOLLICULAR LYMPHOMAS USING INHIBITORS OF  
THE LT PATHWAY*  
Inventors: Browning, Jeffrey, *et al.*  
Filed: July 26, 2000  
Our Ref. No.: BGN-A046CPRCE

Dear Sir:

I enclose herewith for filing in the above-identified application the following:


1. Supplemental Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of references cited in PTO Form SB/08 (5);
4. A copy of the International Search Report; and
5. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any necessary fees in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.


I hereby certify that this correspondence is deposited with the United States Postal Service as first class mail in an envelope addressed to:  
MS Amendment, Commissioner for Patents, P.O. Box 1450,  
Alexandria, Virginia 22313-1450 on:


November 2, 2004

Date

  
Amy E. Mandragouras, Esq. Registration No. 36,207

Respectfully submitted,  
LAHIVE & COCKFIELD, LLP

  
Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Browning, Jeffrey, *et al.*

Serial No.: 09/626,219

Filed: July 26, 2000

For: *TREATMENT OF FOLLICULAR LYMPHOMAS  
USING INHIBITORS OF THE LT PATHWAY*

Attorney Docket No.: BGN-A046CPRCE

Group Art Unit: 1642

Examiner: Misook Yu

MS Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450

Certificate of First Class Mailing (37 CFR §1.8(a))

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450 on the date set forth below.

November 2, 2004

Date of Signature and of Mail Deposit

By:

Amy E. Mandragouras, Esq.

Reg. No. 36,207

Attorney for Applicants

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:


Applicants and their Attorney have become aware of the following publications and information, cited in an International Search Report mailed June 23, 1999 during the prosecution of PCT/US99/01928 which corresponds to the above referenced application. In accordance with 37 CFR §1.97, Applicants hereby submit these publications for the Examiner's consideration. These publications are cited on the enclosed PTO Form SB/08, and a copy of the Report and each publication cited thereon are enclosed as well.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,

LAHIVE & COCKFIELD, LLP




Amy E. Mandragouras, Esq.  
Registration No. 36,207  
Attorney for Applicants

28 State Street  
Boston, MA 02109  
(617) 227-7400

Date: November 2, 2004

AEM/CRC/les  
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/626,219
				Filing Date	July 26, 2000
				First Named Inventor	Browning, Jeffrey
				Art Unit	1642
				Examiner Name	Misoo, Yu
Sheet	1	of	1	Attorney Docket Number	BGN-A046CPRCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	D1	WO 96/01121 A1	01-18-1996	Genentech Inc.		
	D2	WO 97/03687 A1	02-06-1997	Biogen, Inc.		
	D3	EP 0 873 998 A2	10-28-1998	Takeda Chemical Ltd.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	D4	Browning JL, <i>et al.</i> Signaling through the lymphotoxin beta receptor induces the death of some adenocarcinoma tumor lines. J Exp Med. 1996 Mar 1;183(3):867-78.	
	D5	Rennert, <i>et al.</i> Normal development of lymph nodes is disrupted by soluble LTβ receptor – Ig fusion protein. Eur. Cytokine Network. 1996 7:167.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--